September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
45 citations
,
November 2018 in “Journal of dermatological treatment” JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
June 2026 in “Frontiers in Immunology” JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.
June 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
March 2026 in “Expert Opinion on Pharmacotherapy” JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.
3 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
June 2025 in “Medical alphabet” JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.